DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06143956

RecruitingPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight

Assets

Eloralintide / Macupatide / Mazdutide / Tirzepatide

Listed sites

53

Recruiting sites

53

Enrollment

1,481

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Number of Participants Allocated to Each ISA

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06143956
Org study ID18685
Secondary IDW8M-MC-GN01Eli Lilly and Company
Secondary IDW8M-MC-GN02Eli Lilly and Company

Timeline

Milestones

Study start2023-11-17actual
Study first posted2023-11-22actual
Last update posted2026-05-14actual
Primary completion2027-09estimated (month precision)
Study completion2028-02estimated (month precision)

Assets

Investigational agents

EloralintideMacupatideMazdutideTirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have a body mass index (BMI)
–≥30 kilogram/square meter (kg/m²), or
–≥27 kg/m² and <30 kg/m², or with at least 1 weight-related comorbidity
•Have had a stable body weight for the 3 months prior to randomization (<5%) body weight gain and/or loss.

Exclusion criteria

•Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
•Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
•Have poorly controlled hypertension.
•Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
•Have any of the following cardiovascular conditions within 3 months prior to screening:
–acute myocardial infarction
–cerebrovascular accident (stroke)
–unstable angina, or
–hospitalization due to congestive heart failure.
•Have a history of symptomatic gallbladder disease within the past 2 years.
•Have a lifetime history of suicide attempts.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint

Number of Participants Allocated to Each ISA

Time frame:Baseline to Week 6

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.